Categories: News

CRISPR Therapeutics to Host Innovation Day on June 21, 2022

ZUG, Switzerland and CAMBRIDGE, Mass., May 31, 2022 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that it will host an Innovation Day focused on early research and development on Tuesday, June 21, 2022 at 2:00 PM ET.

CRISPR Therapeutics’ Innovation Day will focus on the Company’s differentiated genetic engineering platform technologies, novel approach to cell and gene therapy, and emerging discovery programs.

A live webcast of the event will be available on the “Events & Presentations” page in the Investors section of the Company’s website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company’s website for 30 days following the presentation. Please contact crisprtx@argotpartners.com for any questions regarding the event.

About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

CRISPR THERAPEUTICS® word mark and design logo are trademarks and registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.

Investor Contact:
Susan Kim
+1-617-307-7503
susan.kim@crisprtx.com 

Media Contact:
Rachel Eides
+1-617-315-4493
rachel.eides@crisprtx.com 

Staff

Recent Posts

Richland Aesthetics, Newport Beach’s Luxury Med Spa

Richland Aesthetics in Newport Beach, CA introduces state-of-the-art medspa treatments in a serene, luxurious setting,…

2 hours ago

CardioComm Solutions Provides Update Respecting Debt Settlement

Toronto, Ontario--(Newsfile Corp. - July 8, 2024) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or…

4 hours ago

CONMED Corporation to Announce Second Quarter 2024 Financial Results on July 31, 2024

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced it will report financial results for the…

5 hours ago

AngioDynamics to Report Fiscal 2024 Fourth Quarter and Full-Year Financial Results on July 16, 2024

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on…

5 hours ago

Youth Inventors Compete at The Henry Ford during RTX Invention Convention U.S. Nationals June 5-7, 2024, in Dearborn, Michigan

DEARBORN, Mich., July 8, 2024 /PRNewswire/ -- The Henry Ford hosted over 435 youth inventors…

5 hours ago

Leading Medical Claims Management provider, Medlogix, LLC Announces the Acquisition of ReviewWorks

HAMILTON, N.J., July 8, 2024 /PRNewswire/ -- Medlogix, LLC, a leading, national medical claims management…

5 hours ago